Investigating the Influence of Glycosylation on Protein Conformation and Dynamics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Investigating the Influence of Glycosylation on Protein Conformation and Dynamics
The authors review and discuss the influence of glycans on the conformation of a representative IgG1 biopharmceutical using H/DX-MS as an analytical tool.


Pharmaceutical Technology
Volume 34, pp. s12-s17

15. S.W. Englander and L. Mayne, Annu. Rev. Biophys. Biomol. Struct. 21, 243–265 (1992).

16. V. Katta and B.T. Chait, Rapid Comm. Mass Spec. 5 (4), 214–217 (1991).

17. Z. Zhang and D.L. Smith, Protein Sci. 2 (4), 522–531 (1993).

18. S.W. Englander and N.R. Kallenbach, Q. Rev. Biophys. 16 (4), 134 (1983).

19. T.E. Wales and J.R. Engen, Mass Spectrom. Rev. 25 (1), 158–170 (2006).

20. A.N. Hoofnagle, K.A. Resing, and N.G. Ahn, Annu. Rev. Biophys. Biomol. Struct. 32, 1–25 (2003).

21. J.G. Mandell, A.M. Falick, and E.A. Komives EA, Anal. Chem. 70 (19), 3987–3995 (1998).

22. O.H. Brekke and I. Sandlie, Nat. Rev. Drug Discov. 2 (1), 52–62 (2003).

23. O. Leav, Nat. Rev. Immunol. 10 (5), 297–297 (2010).

24. D. Houde et al., Anal. Chem. 81 (7), 2644–2651 (2009).

25. H.E. Chadd and S.M. Chamow, Curr. Opin. Biotechnol. 12 (2), 188–194 (2001).

26. Y. Mimura et al., Mol. Immunol. 37 (12–13), 697–706 (2000).

27. D. Houde , Mol. Cell. Proteomics 9 (8), 1716–1728 (2010).

28. Y. Yamaguchi et al., Biochem. Biophys. Acta 1760 (4), 693–700 (2006).

29. P. Sondermann et al., Nature 406 (6793), 267–273 (2000).

30. H. Liu and C.G. Bulseco, Immunol. Lett. 106 (2), 144–153 (2006).

31. S. Krapp et al., .J Mol. Biol. 325 (5), 979–989 (2003).

32. A. Okazaki et al., J. Mol. Biol. 336 (5), 1239–1249 (2004).

33. S. Radaev et al., J. Biol. Chem. 276 (19), 16469–16477 (2001).

34. D. Shental–Bechor and Y. Levy, Curr. Opin. Struct. Biol. 19 (5), 524–533 (2009).

35. K.D. Rand et al., Anal. Chem. 81 (14), 5577–5584 (2009).

36. E.O. Saphire et al., Science 293 (5532), 1155–1159 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here